Thursday, March 16, 2023
10:11 AM EST – HLS Therapeutics Inc. : Announces its financial results for the 12-month periods ended December 31, 2022. All amounts are in United States dollars unless otherwise stated. 2022 revenue of $61.5 million, Adjusted EBITDA of $23.8 million and cash-flow from operations of $16.9 million. 2022 net loss was ($23.6) million, compared to net loss of ($13.1) million in 2021. HLS Therapeutics Inc. (T.HLS) shares were down $1.56 at 6.99.
Stocks in Play: HLS Therapeutics Inc., Thu, 16 Mar 2023 10:27:07 EST